Miracor Medical said today that it received breakthrough designation from the FDA for its PiCSO device for treating a type of heart attack. The PiCSO (pressure-controlled intermittent coronary sinus occlusion) system is designed to clear coronary microcirculation by intermittently stopping the delivery of blood through the coronary sinus into the right atrium. The intended result […]
Miracor Medical Systems said today it raised $34.6 million (EU €30 million) Series D round of financing to help support the development and commercialization of its PiCSO Impulse System. The round was led by Ming Capital and co-led by a strategic investor, the Belgium-based company said. The round was also joined by newly invested Belgian […]
Miracor Medical Systems said today it closed a $30.2 million (EU €25 million) round of funding as part of Series D financing round with funds slated to support further development and commercialization of its PiCSO impulse system, and announced it is moving its headquarters from Austria to Belgium. The company’s PiCSO therapy is designed to […]
Zimmer (NYSE:ZMH), who acquired Biomet in a deal that closed this month, announced a series of personnel shifts upon the closure of the merger. Zimmer CFO and senior veep James Crines has stepped down from his position to retire, effective August 3, to be replaced by former CFO and senior veep of BiometDaniel Florin, the company said. […]
Austria’s Miracor Medical Systems is boosting its presence in the U.K. with a new sales office and 2 clinical trials of its heart attack-treatment device.
Private medical device maker Miracor Medical Systems GmbH won CE Mark approval for its Pressure-controlled Intermittent Coronary Sinus Occlusion System.
In conjunction with the regulatory win, the company announced that it successfully treated its 1st patient, a U.K. woman who suffered a large acute heart attack.
MASSDEVICE ON CALL — Standardization is no longer the key to diabetes treatment, according to new guidelines published in the journal Diabetes Care.
Doctors should steer away from encouraging all diabetes patients toward achieving universal blood sugar levels and offer personalized goals based on a patient’s age, overall health and lifestyles preferences.
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.
Private medical device company, Miracor Medical Systems GmbH, secured $10 million in the first closing of the series B financing round. Second closing is pending approval by investors.
Austria Wirtschaftsservice and German venture capital investment group SHS Gesellschaft für Beteiligungsmanagement joined existing investors, Earlybird and Delta Partners, to support Miracor’s financing round.